January 20, 2022 ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma Read Article
July 27, 2021 ImmPACT Bio Announces Completion of Merger with Kalthera to Progress Next-Generation CAR T Therapies for the Treatment of Cancer Read Article
